Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study

被引：0
|
作者：
Lee, Scott D. [1 ]
Vermeire, Severine [2 ]
Ungaro, Ryan C. [3 ]
Durand, Frederick [4 ]
Morris, Nathan [4 ]
Yu, Guanglei [4 ]
Vadhariya, Aisha [4 ]
Traxler, Kristina [4 ]
Fisher, Deborah A. [5 ]
Long, Millie D. [6 ]
机构：
[1] Univ Washington, Med Ctr, Digest Hlth Ctr, Seattle, WA USA
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Eli Lilly & Co, Raleigh, NC USA
[6] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035112.50210.ab
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1436
引用
收藏
页码：S1031 / S1032
页数：2
相关论文
共 50 条
  • [1] Efficacy of Mirikizumab by Baseline Disease Location in Moderately to Severely Active Crohn's Disease: Results of the Phase 3 VIVID-1 Study
    Barnes, Edward
    Bossuyt, Peter
    Ferrante, Marc
    Siegmund, Britta
    Durand, Frederick
    Fisher, Deborah A.
    Morris, Nathan
    Yu, Guanglei
    Bragg, Sonja M.
    Charabaty, Aline
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S739 - S739
  • [2] Improvement in Fatigue With Mirikizumab Therapy and Associations With Clinical Outcomes in Patients With Moderately to Severely Active Crohn's Disease: Results From the PHASE 3 VIVID-1 Study
    Bossuyt, Peter
    Regueiro, Miguel D.
    Fischer, Monika
    Traxler, Kristina
    Yu, Guanglei
    Protic, Marijana
    Tsilkos, Konstantinos
    Vadhariya, Aisha
    Hisamatsu, Tadakazu
    Juillerat, Pascal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S966 - S966
  • [3] Identification of responder subpopulations in moderately-to-severely active Crohn's disease patients treated with mirikizumab: Results from the VIVID-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Yu, G.
    Keefer, L. A.
    Ananthakrishnan, A. N.
    D'Haens, G.
    Deepak, P.
    Kochhar, G. S.
    Melmed, G. Y.
    Chen, Y. F.
    Moses, R. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2061 - i2062
  • [4] Trajectories of response in patients with moderately-to-severely active Crohn's disease treated with mirikizumab or ustekinumab: Post hoc results from the VIVID-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Yu, G.
    Keefer, L. A.
    Ananthakrishnan, A. N.
    D'Haens, G.
    Deepak, P.
    Kocchar, G. S.
    Melmed, G. Y.
    Chen, Y. F.
    Moses, R. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1592 - i1594
  • [5] Trajectories of response in patients with moderately-to-severely active Crohn's disease treated with mirikizumab based on biofailed status: Post hoc results from the VIVID-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Yu, G.
    Keefer, L. A.
    Ananthakrishnan, A. N.
    D'Haens, G.
    Deepak, P.
    Kochhar, G. S.
    Melmed, G. Y.
    Chen, Y. F.
    Moses, R. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1950 - i1951
  • [6] Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn's Disease: Results from a phase 3 clinical trial
    Travis, S.
    Hisamatsu, T.
    Fischer, M.
    Dubinsky, M.
    Jairath, V.
    Chen, M.
    Ferrante, M.
    Peyrin-Biroulet, L.
    Siegmund, B.
    Gibble, T. Hunter
    Lin, Z.
    Protic, M.
    Morris, N.
    Ghosh, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I21 - I23
  • [7] Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn's disease: results from a phase 3 clinical trial
    Ghosh, Subrata
    Chen, Minhu
    Fischer, Monika
    Dubinsky, Marla
    Jairath, Vipul
    Hisamatsu, Tadakazu
    Ferrante, Marc
    Peyrin-Biroulet, Laurent
    Siegmund, Britta
    Gibble, Theresa
    Lin, Zhantao
    Protic, Marijana
    Morris, Nathan
    Travis, Simon
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 : S16 - S17
  • [8] MIRIKIZUMAB IMPROVES FATIGUE, BOWEL URGENCY, AND QUALITY OF LIFE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM A PHASE 3 CLINICAL TRIAL
    Ghosh, Subrata
    Chen, Minhu
    Fischer, Monika
    Dubinsky, Marla C.
    Jairath, Vipul
    Hisamatsu, Tadakazu
    Ferrante, Marc
    Peyrin-Biroulet, Laurent
    Siegmund, Britta
    Gibble, Theresa H.
    Lin, Zhantao
    Protic, Marijana
    Morris, Nathan
    Travis, Simon P.
    GASTROENTEROLOGY, 2024, 166 (05) : S850 - S851
  • [9] Lack of significance of treatment-emergent anti-drug antibodies on efficacy of mirikizumab in patients with moderately-to-severely active Crohn's Disease: Results from the VIVID-1 study
    Jairath, V
    Ananthakrishnan, A.
    Ben-Horin, S.
    D'Haens, G.
    Hisamatsu, T.
    Sands, B.
    Fisher, D. A.
    Protic, M.
    Moses, R.
    Yu, G.
    Chan-Diehl, F.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i200 - i201
  • [10] Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease
    Chua, L.
    Otani, Y.
    Friedrich, S.
    Durand, F.
    Zhang, X.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1873 - I1873
12345